Lung cancer gene test and blood clot risk study
Part of Cancer, Heart & circulation, Lungs & breathing clinical trials.
This study looks at whether certain gene profiles in advanced lung cancer affect the risk of blood clots. It may help doctors better understand and prevent clots in people starting new cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have advanced or metastatic non-small-cell lung cancer (stage 3 or 4)
- You are about to start a new cancer treatment (first or later line of therapy)
- You have had tests for certain genes (like EGFR, KRAS, ALK, ROS1, and PD-1/PD-L1)
- You have not had surgery, radiation, or chemotherapy for lung cancer too recently
- You have not had a blood clot after your cancer diagnosis or used blood thinners regularly
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced non-small cell lung cancer (NSCLC) who have not yet started treatment. It studies a simple blood test that checks for genetic changes in the cancer, to help doctors choose the most effective first treatment.
This study looks at why some people develop blood clots after lung cancer surgery. By tracking your recovery for 30 days, researchers hope to find better ways to predict and prevent clots in the future.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This study tests whether a blood test (liquid biopsy) can help doctors better understand your lung cancer and plan your treatment. You'll have a blood sample taken alongside standard biopsies to see if the blood test provides useful information about your cancer.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new Venous Thromboembolism (VTE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.